Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of antibacterials to treat multi-drug resistant (MDR), gram-negative infections. It is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). It initiated a Phase III trial of plazomicin in the first quarter of 2014. In addition, to plazomicin, its research and development pipeline includes two programs that specifically target infections caused by Pseudomonas aeruginosa, which it refers to as antipseudomonal programs. The first is a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and the second is a therapeutic antibody program. It is also pursuing small molecule research programs.